

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Atogepant for treating migraine ID6615

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AbbVie (atogepant)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Pain	Board of Community Health Councils in
Brain and Spine Foundation	Wales
Brain Charity	British National Formulary
Migraine Action	Care Quality Commission
Migraine Trust	Department of Health - Northern Ireland
National Migraine Centre National Alliana	Healthcare Improvement Scotland Madicines and Use Illustrations
Neurological Alliance OLICIA III	Medicines and Healthcare products Pagulatory Agency
OUCH UK Dais Constants	Regulatory Agency
Pain Concern Pain Police Foundation	National Association of Primary Care National Pharmacy Association
Pain Relief Foundation Dain LIK	National Pharmacy Association Neurological Alliance of Sectland
Pain UK South Asian Health Foundation	Neurological Alliance of ScotlandNHS Confederation
South Asian Health Foundation Specialized Lighthern Alliance	
Specialised Healthcare Alliance	NHS Wales Joint Commissioning Committee
Healthcare professional groups	Scottish Medicines Consortium
 Association of British Neurologists 	Wales Neurological Alliance
British Association for the Study of Headache	Welsh Government
British Geriatrics Society	Possible comparator companies
British Neuropathological Society	Pfizer (rimegepant)
British Pain Society	
Institute of Neurology	Relevant research groups
National Neuroscience Advisory	Brain Research UK
Group	Cochrane Pain, Palliative Care and
Neuromodulation Society of UK and	Supportive Care Group
Ireland	Genomics England
Physiotherapy Pain Association	MRC Clinical Trials Unit
 Primary Care and Community Neurology Society 	 National Hospital for Neurology and Neurosurgery
Royal College of Anaesthetists	National Institute for Health Research
 Royal College of General Practitioners 	Pain Relief Foundation
Royal College of Nursing	
Royal College of Pathologists	Associated Public Health groups
	Public Health Wales

Provisional stakeholder list for the evaluation of atogepant for treating migraine ID6615 Issue date: -October2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association 	UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of atogepant for treating migraine ID6615 Issue date: -October2025